Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
MaxCyte to Participate in Two Upcoming Investor Conferences
-
Euro Sun Mining and Glencore Enter into MOU for Concentrate Offtake
-
Nanox Highlighted on TIME's Best Inventions of 2024 List for its AI Solutions
-
Standard BioTools to Participate in Upcoming Investor Conferences
-
Uniti Group Inc. Reports Third Quarter 2024 Results
-
Nanox Highlighted on TIME's Best Inventions of 2024 List for its AI Solutions
-
Greif, Inc. Announces 2024 Fourth Quarter Earnings Release and Conference Call Dates
-
FlexShopper and PayPossible Expand Consumer Payment Options Through Strategic Partnership
-
Woodward Schedules Fiscal 2024 Fourth Quarter and Full Year Earnings Release and Conference Call
-
OpenTable and Visa Team Up to Offer Exclusive Dining Access in Canada
-
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
-
First Mid Bancshares, Inc. Announces Third Quarter 2024 Results
-
EBYH Broadcasts Media Kit for the Inaugural 1-Million Strong Killing Cancers, Fight Club, VIP Fundraiser Event, Pre-Sales for Event Sponsorships and VIP Tickets, Final Venue Choice and Inaugural Event
-
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
-
Reviva to Participate in the UBS Global Healthcare Conference
-
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
-
U.S. Energy Corp. Announces Major Helium Discovery from Initial Development Program
-
Integral Metals Corp. Announces Listing of Common Shares on the CSE
-
Sow Good to Hold Third Quarter 2024 Conference Call on Thursday, November 14, 2024 at 10:00 a.m. ET
-
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
-
Global Uranium Corp. Completes Survey Work on Wyoming Claims, Collecting Radiometric and Drone Imagery Data
-
Recce Pharmaceuticals Announces Interim Efficacy Data and Safety Approval for Phase II ABSSSI Clinical Trial
-
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
-
The ALS Society of Canada celebrates $13 million investment into Ontario Provincial ALS Program
-
Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer
-
Nuwellis Welcomes University of Iowa Health Care Stead Family Children’s Hospital as Newest Pediatric Customer
-
Bionano Announces $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Inovalon’s Converged Quality Solution Customers Realized a 5% Increase in Star Ratings Score, Including Nearly 60% of All Medicare Health Plans Which Received CMS’ Highest 5-Star Rating
-
Ovid Therapeutics to Host Investor Event
-
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
-
Athene Announces CFO Martin P. Klein to Retire from Role
-
Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
-
PodcastOne Engages MZ Group to Lead Strategic Investor Relations Program
-
aTyr Pharma to Present at Upcoming Investor Conferences
-
Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction
-
Konica Minolta Healthcare and Quinsite Partner to Bring Comprehensive Workflow and Operational Analytics to Exa Platform Users
-
BD² and DBSA Partner to Improve the Lives of People Living With Bipolar Disorder
-
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
-
UYBA Volley Battles Back with Consecutive Wins in Serie A1
-
Nearly 80% of Consumers Consider Phone Channel Important for Communicating with Businesses, Despite Reluctance to Answer Calls
-
Sensus Healthcare to Host Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 14, 2024
-
Outbrain Deepens Collaboration with Microsoft – Integrates AI Solutions into Its Offerings
-
The Geological Society of America Acquires Mountain Press Publishing Company’s Renowned Geology Book Series
-
Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins
-
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
-
Crown to Report Third Quarter 2024 Results on November 14, 2024
-
IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
-
Deepfake Fraud Costs the Financial Sector an Average of $600,000 for Each Company, Regula’s Survey Shows
-
Solid Biosciences to Participate at the Truist Securities BioPharma Symposium
-
Monster Beverage to Report Financial Results for 2024 Third Quarter on November 7, 2024

